| 7.45 -0.19 (-2.49%) | 10-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.96 |
1-year : | 10.9 |
| Resists | First : | 8.53 |
Second : | 9.34 |
| Pivot price | 7.6 |
|||
| Supports | First : | 7.21 | Second : | 6 |
| MAs | MA(5) : | 7.47 |
MA(20) : | 7.77 |
| MA(100) : | 8.33 |
MA(250) : | 10.21 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 22 | D(3) : | 19.4 |
| RSI | RSI(14): 37.5 |
|||
| 52-week | High : | 14.51 | Low : | 6.96 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ARVN ] has closed above bottom band by 35.8%. Bollinger Bands are 24.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.69 - 7.73 | 7.73 - 7.76 |
| Low: | 7.35 - 7.39 | 7.39 - 7.42 |
| Close: | 7.39 - 7.45 | 7.45 - 7.51 |
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Mon, 12 Oct 2026
Brummer Multi-Strategy AB's Arvinas Inc(ARVN) Holding History - GuruFocus
Sun, 11 Oct 2026
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Fri, 09 Oct 2026
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO) - The Globe and Mail
Fri, 09 Oct 2026
Arvinas Q3 2026 Earnings Date and Estimates - MarketBeat
Thu, 08 Oct 2026
Arvinas, Inc. (ARVN) stock price, news, quote and history - Yahoo Finance UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 5.681e+007 (%) |
| Held by Institutions | 7.8 (%) |
| Shares Short | 4,710 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.9e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 2.9 % |
| Operating Margin | 66.3 % |
| Return on Assets (ttm) | -1.1 % |
| Return on Equity (ttm) | 1.5 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 8.12 |
| Sales Per Share | 1.74972e+008 |
| EBITDA (p.s.) | 1.7e+008 |
| Qtrly Earnings Growth | 0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -207 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.56 |
| Dividend | 0 |
| Forward Dividend | 5.39e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|